JP2010518023A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518023A5 JP2010518023A5 JP2009548470A JP2009548470A JP2010518023A5 JP 2010518023 A5 JP2010518023 A5 JP 2010518023A5 JP 2009548470 A JP2009548470 A JP 2009548470A JP 2009548470 A JP2009548470 A JP 2009548470A JP 2010518023 A5 JP2010518023 A5 JP 2010518023A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- norepinephrine
- antagonism
- dopamine
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 230000003042 antagnostic Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drugs Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 3
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 claims 3
- 229960002748 Norepinephrine Drugs 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000001747 exhibiting Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000000966 norepinephrine reuptake Effects 0.000 claims 3
- 230000012154 norepinephrine uptake Effects 0.000 claims 3
- 206010004938 Bipolar disease Diseases 0.000 claims 2
- 102000004980 Dopamine D2 Receptors Human genes 0.000 claims 2
- 108090001111 Dopamine D2 Receptors Proteins 0.000 claims 2
- 229960003955 Mianserin Drugs 0.000 claims 2
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Tolvon Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims 2
- 239000000442 dopamine 2 receptor blocking agent Substances 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- -1 lacloprid Chemical compound 0.000 claims 2
- 230000003364 opioid Effects 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims 1
- JLOAJISUHPIQOX-UHFFFAOYSA-N 6-piperazin-1-ylbenzo[b][1,4]benzothiazepine Chemical compound C1CNCCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 JLOAJISUHPIQOX-UHFFFAOYSA-N 0.000 claims 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N Amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims 1
- 229940025084 Amphetamine Drugs 0.000 claims 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 1
- HSWPZIDYAHLZDD-UHFFFAOYSA-N Atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 claims 1
- 229960003002 Atipamezole Drugs 0.000 claims 1
- 229960001058 Bupropion Drugs 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N Bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N Buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 1
- 241000218236 Cannabis Species 0.000 claims 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N Chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims 1
- 229960001076 Chlorpromazine Drugs 0.000 claims 1
- 101700040453 DRD2 Proteins 0.000 claims 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 1
- 229960002690 Fluphenazine Drugs 0.000 claims 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine dihydrochloride Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N Haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 1
- 229940120060 Heroin Drugs 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 229950001476 IDAZOXAN Drugs 0.000 claims 1
- HPMRFMKYPGXPEP-UHFFFAOYSA-N Idazoxan Chemical compound N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 claims 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N Iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N Imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N Maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims 1
- 206010061284 Mental disease Diseases 0.000 claims 1
- SLVMESMUVMCQIY-UHFFFAOYSA-N Mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 claims 1
- 229960000300 Mesoridazine Drugs 0.000 claims 1
- 229960001785 Mirtazapine Drugs 0.000 claims 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N Mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- ITJNARMNRKSWTA-UHFFFAOYSA-N Nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 claims 1
- 229950004211 Nisoxetine Drugs 0.000 claims 1
- 229960001158 Nortriptyline Drugs 0.000 claims 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims 1
- 229940005483 OPIOID ANALGESICS Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N Olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 229940105606 Oxycontin Drugs 0.000 claims 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycontin Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 1
- 229960000762 Perphenazine Drugs 0.000 claims 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 claims 1
- 229960003418 Phenoxybenzamine Drugs 0.000 claims 1
- 206010037175 Psychiatric disease Diseases 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N Quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- CBQGYUDMJHNJBX-RTBURBONSA-N Reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims 1
- 229960001534 Risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N Risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Tranquisan Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 claims 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N Ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 1
- 229960002734 amfetamine Drugs 0.000 claims 1
- 229960004372 aripiprazole Drugs 0.000 claims 1
- 229960002495 buspirone Drugs 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 1
- ZPUCINDJVBIVPJ-BARDWOONSA-N cocaine Natural products O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 claims 1
- 229960003914 desipramine Drugs 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960003878 haloperidol Drugs 0.000 claims 1
- 229960003162 iloperidone Drugs 0.000 claims 1
- 229960004801 imipramine Drugs 0.000 claims 1
- 229960003299 ketamine Drugs 0.000 claims 1
- 229960004090 maprotiline Drugs 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- 229960002085 oxycodone Drugs 0.000 claims 1
- 229960001057 paliperidone Drugs 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- 229960003770 reboxetine Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229960004940 sulpiride Drugs 0.000 claims 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 claims 1
- 229960000317 yohimbine Drugs 0.000 claims 1
- 229960000607 ziprasidone Drugs 0.000 claims 1
Claims (12)
- 下記を示す薬剤の組み合わせを含む、アルコールもしくは他の物質の乱用もしくは依存を有するかまたはそのリスクを有する患者を治療するための薬学的組成物:
(a)ドーパミンD2受容体遮断(拮抗作用);および
(b)ノルエピネフリン再取り込み阻害。 - 組成物がノルエピネフリンα2受容体遮断(拮抗作用)をさらに示す、請求項1記載の薬学的組成物。
- 乱用物質に下記の1つまたは複数が含まれる、請求項1記載の薬学的組成物:アルコール、1つまたは複数のオピオイド、大麻、コカイン、アンフェタミン、タバコ。
- オピオイドがヘロイン、oxyContin(商標)、または両方である、請求項3記載の薬学的組成物。
- D2受容体遮断を示す薬剤が、弱いドーパミンD2受容体アンタゴニスト(遮断剤)である、請求項1または請求項2記載の薬学的組成物。
- 患者が統合失調症または双極性障害などの併発する精神障害を示さない、請求項1記載の薬学的組成物。
- 患者が統合失調症または双極性障害などの併発する精神障害を示す、請求項1記載の薬学的組成物。
- 組成物が、ドーパミンD2受容体アンタゴニスト活性を示す薬剤として、リスペリドン、パリペリドン、ハロペリドール、オランザピン、クエチアピン、ジプラシドン、アリピプラゾール、イロペリドン、フルフェナジン、クロルプロマジン、トリフルオペリジン、モリンドン、ペルフェナジン、メソリダジン、ラクロプリド、スルピリド、アミスルピリドを含む群より選択される薬物を含む、請求項1記載の薬学的組成物。
- 組成物が、ノルエピネフリンα2受容体アンタゴニストとして、イダゾキサン、ヨヒンビン、アチパメゾール、ミルタザピン、ミアンセリン、フェノキシベンザミン、ブスピロン、ミアンセリンを含む、請求項2記載の薬学的組成物。
- 組成物が、ノルエピネフリン再取り込み阻害を示す薬剤として、デシプラミン、レボキセチン、ノルトリプチリン、アタモキセチン、マプロチリン、ニソキセチン、イミプラミン、ブプロピオン、ケタミン、n-デスアルキルクエチアピンを含む、請求項1記載の薬学的組成物。
- (a)ドーパミンD2受容体遮断(拮抗作用);および(b)ノルエピネフリン再取り込み阻害を含む、薬剤。
- ノルエピネフリンα2受容体遮断(拮抗作用)をさらに含む、請求項11記載の薬剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88765707P | 2007-02-01 | 2007-02-01 | |
US711707P | 2007-12-11 | 2007-12-11 | |
PCT/US2008/052811 WO2009014770A2 (en) | 2007-02-01 | 2008-02-01 | Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010518023A JP2010518023A (ja) | 2010-05-27 |
JP2010518023A5 true JP2010518023A5 (ja) | 2011-05-06 |
Family
ID=39676697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009548470A Pending JP2010518023A (ja) | 2007-02-01 | 2008-02-01 | ドーパミンD2受容体遮断剤とノルエピネフリン再取り込み阻害剤およびノルエピネフリンα2受容体遮断剤との組み合わせ |
Country Status (6)
Country | Link |
---|---|
US (2) | US9044471B2 (ja) |
EP (2) | EP2457571A1 (ja) |
JP (1) | JP2010518023A (ja) |
AU (1) | AU2008279572A1 (ja) |
CA (1) | CA2677219A1 (ja) |
WO (1) | WO2009014770A2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016104367A1 (ja) * | 2014-12-22 | 2016-06-30 | 株式会社Lttバイオファーマ | 機能性ディスペプシア治療薬 |
US11207322B2 (en) | 2017-04-28 | 2021-12-28 | Board Of Regents, The University Of Texas System | Method and composition related to combination therapy for addiction |
AU2018378348A1 (en) | 2017-12-05 | 2020-06-18 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
WO2019113079A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
CA3142355A1 (en) | 2019-06-04 | 2020-12-10 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
CN117338772B (zh) * | 2023-11-22 | 2024-04-09 | 徐州医科大学 | 一种药物组合物及其在制备用于预防和/或治疗重性抑郁障碍的药物中的应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159963A (en) * | 1996-03-29 | 2000-12-12 | Eli Lilly And Company | Method for treating substance abuse |
US6348455B1 (en) * | 1998-11-23 | 2002-02-19 | Sepracor Inc. | Desmetylolanzapine compositions and methods |
CA2352611A1 (en) * | 1998-11-23 | 2000-06-02 | Sepracor Inc. | 2-hydroxymethylolanzapine compositions and methods |
EP1336406A1 (en) | 2002-02-14 | 2003-08-20 | Solvay Pharmaceuticals B.V. | Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity |
US20060189599A1 (en) * | 2002-10-18 | 2006-08-24 | Green Alan I | Treating alcohol and or substance abuse by antagonizing alpha 2 adrenergic receptors with weak dopamine blocking |
EP1713486A4 (en) * | 2003-12-02 | 2009-04-29 | Sheldon Leslie James | COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY |
CA2576505A1 (en) * | 2004-08-03 | 2006-02-16 | Orexigen Therapeutics, Inc. | Combination of bupropion and a second compound for affecting weight loss |
JP2006071612A (ja) * | 2004-09-06 | 2006-03-16 | Niigata Tlo:Kk | 学習機能障害評価方法、及び学習機能障害評価用装置 |
CN101208092A (zh) * | 2005-05-31 | 2008-06-25 | 奥雷西根治疗公司 | 用于处理精神障碍的方法和组合物 |
WO2008079728A2 (en) * | 2006-12-22 | 2008-07-03 | Allergan, Inc. | Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain |
EP2485712A1 (en) * | 2009-10-06 | 2012-08-15 | Ascendis Pharma A/S | Subcutaneous paliperidone composition |
-
2008
- 2008-02-01 WO PCT/US2008/052811 patent/WO2009014770A2/en active Search and Examination
- 2008-02-01 JP JP2009548470A patent/JP2010518023A/ja active Pending
- 2008-02-01 US US12/024,950 patent/US9044471B2/en not_active Expired - Fee Related
- 2008-02-01 EP EP12156587A patent/EP2457571A1/en not_active Withdrawn
- 2008-02-01 CA CA002677219A patent/CA2677219A1/en not_active Abandoned
- 2008-02-01 EP EP08826643A patent/EP2114150A4/en not_active Withdrawn
- 2008-02-01 AU AU2008279572A patent/AU2008279572A1/en not_active Abandoned
-
2015
- 2015-06-01 US US14/727,339 patent/US20150374712A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010518023A5 (ja) | ||
JP2016539144A5 (ja) | ||
JP2010535220A5 (ja) | ||
CN101506172A (zh) | (7S)-7-[(5-氟-2-甲基-苄基)氧基]-2-[(2R)-2-甲基哌嗪-1-基]-6,7-二氢-5H-环戊烷并[b]吡啶的酒石酸盐 | |
WO2006067496A1 (en) | Combination of sabcomeline with a neuroleptic agent to treat psychotic disorders | |
WO2008000469A3 (en) | Nicotinic agonists selective for the alpha7 receptor subtype, the process for the preparation thereof and pharmaceutical compositions therefrom | |
WO2009013212A3 (en) | Dual modulators of 5-ht2a and d3 receptors | |
CA2713025A1 (en) | Kappa selective opioid receptor antagonist | |
TWI331919B (en) | 5-ht1a receptor subtype agonist | |
US20150374712A1 (en) | Combinations of Dopamine D2 Receptor Blockade With Norepinephrine Reuptake Inhibition and with Norepinephrine Alpha 2 Receptor Blockade | |
CN107001367A (zh) | 用于治疗例如注意力缺陷障碍(add)的作为人多巴胺主动转运体(dat)蛋白抑制剂的2‑[双(4‑氟苯基)甲基]‑2,7‑二氮杂螺[4.5]癸烷‑10‑酮衍生物和有关化合物 | |
AU2020205268B2 (en) | Use of phenoxypropylamine compounds to treat depression | |
WO2007137224A2 (en) | Method of treatment | |
KR20130101524A (ko) | 5-ht2c 아고니스트의 비-흡습성 염 | |
EP3057595B1 (en) | Fused benzazepines for treatment of stuttering | |
JP2015510926A5 (ja) | ||
US20020094986A1 (en) | Combination treatment for depression, anxiety and psychosis | |
MX2009004615A (es) | Derivados de eter como moduladores duales de los receptores de 5-hidroxitriptamina a (5-ht2a) y dopamina (d3). | |
CN105263922B (zh) | 三唑化合物及其作为γ分泌酶调节剂的用途 | |
CA2666630A1 (en) | Agent for prophylaxis or treatment of alcohol dependence or drug dependence | |
US20060025434A1 (en) | Therapeutic agents for drug/substance dependence | |
JPWO2008102859A1 (ja) | 不安障害の予防および/または治療薬 | |
McNamara et al. | Comparative Preclinical Efficacy of Combivent and a Novel, Bifunctional Muscarinic Antagonist and β2-Adrenergic Agonist. | |
NZ719103B2 (en) | Fused benzazepines for treatment of stuttering | |
NZ544232A (en) | Substituted 1,4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opoid-based treatments |